>Improving sales momentum is partially offset by SG&A inflation - Total Q3 revenues reached € 119m (+9% y-o-y vs 9% sales growth registered in Q2), a touch ahead of our estimate and the consensus. By division, sales of traditional products in Spain posted some sequential improvement (10% y-o-y in Q3 2024 vs 4% in Q2 and 14% in Q1), reflecting the positive impact that new formats are having in Bilastine that are offsetting the price reductions (+11% in Q3 vs -2% in Q2 ...
>Sales lose momentum in Iberia and Animal health but the Exports save the quarter - Total Q2 revenues reached € 134m (+9% y-o-y vs 7% sales growth registered in Q1), a touch ahead of our estimate. By division, sales of traditional products in Spain posted some sequential deterioration (4% y-o-y in Q2 2024 vs 14% in Q1), reflecting a softening of momentum in Bilastine (-2% in Q2 vs +5% in Q1) and flattish Mesalazine which were partially offset by a good evolution of Ca...
>Momentum mirage before the SG&A and R&D hump expected from Q2 onwards - Total Q1 2024 revenues reached € 139m (+7% y-o-y vs 4% sales growth registered in Q4), a touch ahead of our estimate. By division, sales of traditional products in Spain posted some sequential improvement (14% y-o-y in Q1 2024 vs 4% in Q4), reflecting improving momentum in Bilastine (ophthalmic and ODT versions recently launched partially offsetting the generic competition in the regular version)...
>FY 2024 likely to be, yet another, transition year with limited earnings growth - FY 2023 was a record year in terms of earnings, but total shareholder return was negative (-5%). The year was marked by post-patent decline in Europe of its key product Bilastine and weak trends for its animal health unit (sales -17% in Q4 2023), impacted by the lower swine livestock in Europe because of the swine flu, factors that were offset by market expansion in LatAm and the resi...
>Modest sales momentum, slightly softer margins - Total Q4 2023 revenues reached € 108m (+4% y-o-y vs 4% sales growth registered in Q3), broadly in line with our estimates. By division, sales of traditional products in Spain posted some sequential deterioration yet remained in positive territory y-o-y (4% y-o-y in Q4 2023 vs 6% in Q3), reflecting improving momentum in Bilastine (ophthalmic and ODT versions recently launched partially offsetting the generic competition...
>Sales momentum improves slightly while margins post a modest deterioration - Q3 2023 sales reached € 107m (+5% y-o-y vs +3% in Q2 2023, +2% in Q1 2023 and +2% in Q4 2022). By division, sales of traditional products in Spain posted a material sequential improvement and returned to growth territory (+6% y-o-y vs -1% in Q2 2023, -4% in Q1 2023 and -7% in Q4 2022), reflecting higher dynamism in Bilastine (ophthalmic and ODT versions recently launched partially offsetting...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.